Showing results (151-160 of 232) with videos related to

Sort By:
Pageof 24
Journal of Crohn'S & Colitis|January 12, 2018
Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMTJohn A Snowden, Julián Panés, Tobias Alexander, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
The American Journal of Gastroenterology|December 1, 2007
Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and predictionPeggy Vandewalle-El Khoury, Jean-Frederic Colombel, Sofie Joossens, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.
NPJ Genomic Medicine|September 13, 2022
Machine learning-based detection of immune-mediated diseases from genome-wide cell-free DNA sequencing datasetsHuiwen Che, Tatjana Jatsenko, Lore Lannoo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 7, 2026
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension TrialBruce E Sands, Edward L Barnes, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 studySeverine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Nature Communications|October 1, 2014
A20 controls intestinal homeostasis through cell-specific activitiesLars Vereecke, Sara Vieira-Silva, Thomas Billiet, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2025
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trialBruce E Sands, Remo Panaccione, Geert D'Haens, et al.
Pageof 24